

LITE Publication Policy

Purpose and Scope

Publication is an important aspect of the LRRK2 Investigative Therapeutic Exchange (LITE). This policy outlines guidelines for authorship, data citation, administrative review, and open science compliance for LITE publications, including publications utilizing LITE data or biospecimens.

Policy Objectives

This policy ensures that:

- LITE data is published fully, accurately, and expeditiously
- Publications can be tracked to develop a complete record of findings from LITE
- LITE data used in publications are cited accurately
- Publications authored by investigators are accessible online and free of cost or other access barriers by following principles of Open Access (“OA”), which facilitates the rapid and free exchange of scientific ideas and ensures that research can be leveraged for future discoveries.
- Publications adhere to open science standards required by The Michael J. Fox Foundation for Parkinson's Research. Please refer to the MJFF Open Science Policy below, or contact openscience@michaeljfox.org if you have questions.

LITE Data Use and Publications Committee (DPC)

A LITE Data Use and Publications Committee will be established to conduct administrative compliance reviews of all publications generated using LITE funding and/or LITE data. The DPC will comprise members from LITE leadership, site investigators, and LITE Steering Committee (LITE SC) representatives. The DPC reviews manuscripts only for administrative compliance, **not scientific quality**, to ensure accurate data citation and appropriate acknowledgment of sponsors and partners. Appeals of DPC decisions may be directed to the LITE SC.

LITE Publication Categories

Pillar 1 & 2 LITE Consortium-Authored Publications

Pillar 1 & 2 LITE Consortium-Authored publications are reports, analyses, and publications authored or directly supported by LITE investigators. This includes the LITE Steering Committee, LITE member investigators, and investigators supported by LITE. Categories include publications that fulfill the LITE's primary objectives and/or whose core results substantively rely on LITE outputs such as LITE data, methods, tooling, or infrastructure. Examples include primary data manuscripts, exploratory manuscripts, partnership manuscripts, methods manuscripts, perspectives, reviews, and white papers.

In certain instances, Pillar 1 & 2 LITE Consortium-Authored publications will be required to include the phrase “and the LRRK2 Investigative Therapeutics Exchange*” at the end of the author line as directed by the LITE SC or DPC. The asterisk refers to the [LITE Banner Author List](#), which may be required for inclusion in the manuscript. Inclusion and final placement of the LITE Banner Author List (by-line authorship vs. acknowledgments, and how the LITE Banner Author List is presented within the manuscript) will be

decided by the manuscript's lead/corresponding authors in consultation with the LITE SC and DPC, based on documented contributions and common research publication authorship standards. Otherwise, all Pillar 1 & 2 LITE Consortium-Authored publications will be required to acknowledge LITE in the acknowledgement section as referenced below.

Pillar 3 LITE Consortium-Authored Publications

Pillar 3 LITE Consortium-Authored publications are reports, analyses, and publications authored or directly supported by LITE investigators using biospecimens and/or clinical data, imaging data and/or data generated from biospecimens that are collected as part of LITE. This includes the LITE Steering Committee, LITE member investigators, Study Cores, and Working Groups. Categories include publications that fulfill the study's primary objectives, primary data manuscripts, exploratory manuscripts, partnership manuscripts, and methods manuscripts. Potential authors should:

- Early in the publication planning process, share the analysis with the LITE Steering Committee confidentially; AND
- Prior to submission, submit analytic data sets and statistical codes to Dundee for review.

In certain instances, Pillar 3 LITE Consortium-Authored publications will be required to include the phrase "and the LRRK2 Investigative Therapeutics Exchange*" at the end of the author line as directed by the LITE SC or DPC. The asterisk refers to the [LITE Banner Author List](#), which may be required for inclusion in the manuscript. Inclusion and final placement of the LITE Banner Author List (by-line authorship vs. acknowledgments, and how the LITE Banner Author List is presented within the manuscript) will be decided by the manuscript's lead/corresponding authors in consultation with the LITE SC and DPC, based on documented contributions and common research publication authorship standards. Otherwise, all Pillar 3 LITE Consortium-Authored publications will be required to acknowledge LITE in the acknowledgement section as referenced below.

ALL LITE Consortium-Authored Publications must be sent to both the LITE SC and DPC for review prior to journal submission.

External Publications

External Publications are authored by investigators not involved with the LITE study or, in some cases, by LITE investigators working outside their formal LITE role for purposes of a given publication.

External Publications include:

- Publications by investigators outside of the LITE study who will conduct research and analyses using LITE data and specimens. These individuals are encouraged to publish novel scientific findings that result from their research using LITE data and biospecimens; OR
- Publications that only reference LITE without relying on LITE outputs (LITE data, methods, tooling, or infrastructure) or funding support from LITE.

External Publications are to be submitted to the DPC for administrative review prior to journal submission. The purpose of this review is to track External Publications and ensure appropriate attribution of the study and study sponsor and partners. The DPC does not review content.

In certain instances, External Publications may be required to acknowledge LITE in the acknowledgement section as referenced below.

LITE Publication Requirements

Required Acknowledgments

Pillar 1 & 2

All Pillar 1 and relevant Pillar 2 LITE Consortium-Authored publications must acknowledge funding support from LITE. To do so, include the following statement:

“This work was supported by the LRRK2 Investigative Therapeutics Exchange (LITE)*, a collaborative research initiative of The Michael J. Fox Foundation for Parkinson’s Research (MJFF) (<https://ror.org/03arq3225>) and implemented by the University of Dundee (<https://ror.org/03h2bxq36>). LITE is designed to promote precompetitive collaboration among academic, clinical, and industry partners to advance the development of LRRK2-targeted therapeutics and the discovery and validation of biomarkers for Parkinson’s disease.”

The asterisk refers to the [LITE Banner Author List](#), which may be required for inclusion in the manuscript. Inclusion and final placement of the LITE Banner Author List (by-line authorship vs. acknowledgments, and how the LITE Banner Author List is presented within the manuscript) will be decided by the manuscript’s lead/corresponding authors in consultation with the LITE SC and DPC, based on documented contributions and common research publication authorship standards.

Additionally, Pillar 1 LITE Consortium-Authored publications should include the following:

- “The study is funded by the joint efforts of The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and the LRRK2 Investigative Therapeutics Exchange (LITE) initiative. The University of Dundee administered the grant (Grant ID: MJFF-025924) on behalf of LITE and itself.”
- Affiliation as outlined below:
Your Home Institution & Address
LRRK2 Investigative Therapeutics Exchange (LITE), New York, NY 10120

Pillar 3

All Pillar 3 LITE Consortium-Authored publications must acknowledge LITE as the data and/or resource source and must acknowledge funding support. To do so, include the following two statements with the bracketed information updated:

“Data and/or biospecimens used in the preparation of this article were obtained on [YYYY-MM-DD] from the LRRK2 Investigative Therapeutics Exchange (LITE) program [insert database or access URL if applicable]. For up-to-date information on the study, visit <https://www.michaeljfox.org/lrrk2-investigative-therapeutics-exchange-lite>.

This work was supported by the LRRK2 Investigative Therapeutics Exchange (LITE)*, a collaborative research initiative of The Michael J. Fox Foundation for Parkinson’s Research (MJFF) (<https://ror.org/03arq3225>) and implemented by the University of Dundee (<https://ror.org/03h2bxq36>). LITE is designed to promote precompetitive collaboration among academic, clinical, and industry partners

to advance the development of LRRK2-targeted therapeutics and the discovery and validation of biomarkers for Parkinson's disease."

The asterisk refers to the [LITE Banner Author List](#), which may be required for inclusion in the manuscript. Inclusion and final placement of the LITE Banner Author List (by-line authorship vs. acknowledgments, and how the LITE Banner Author List is presented within the manuscript) will be decided by the manuscript's lead/corresponding authors in consultation with the LITE SC and DPC, based on documented contributions and common research publication authorship standards.

External Publications

External Publications that utilize LITE data and/or biospecimens must acknowledge LITE as the data and/or resource source. To do so, include the following statement with the bracketed information updated:

"Data and/or biospecimens used in the preparation of this article were obtained on [YYYY-MM-DD] from the LRRK2 Investigative Therapeutics Exchange (LITE) program [insert database or access URL if applicable]. For up-to-date information on the study, visit <https://www.michaeljfox.org/lrrk2-investigative-therapeutics-exchange-lite>. LITE is a collaborative research initiative of The Michael J. Fox Foundation for Parkinson's Research (MJFF) (<https://ror.org/03arq3225>) and implemented by the University of Dundee (<https://ror.org/03h2bxq36>). LITE is designed to promote precompetitive collaboration among academic, clinical, and industry partners to advance the development of LRRK2-targeted therapeutics and the discovery and validation of biomarkers for Parkinson's disease."

All authors are to notify the DPC upon publication of a submitted manuscript.

LITE Open Science Policy

LITE Consortium-Authored publications must adhere to the MJFF Open Science Policy at this link: <https://doi.org/10.5281/zenodo.18778011>, which provides guidance and requirements for open sharing of research outputs, including, but not limited to: data, publications, code, and software. The MJFF Open Science Policy weblink provided here always supersedes information contained in the attached appendix. Definitions of governed outputs are provided in the MJFF Open Science Policy.

Publications must adhere to the following to be compliant with MJFF's Open Science Policy:

- Public access to submitted manuscripts at the time of submission.
 - Manuscripts prepared by LITE Consortium members must be posted on a publicly accessible preprint platform (e.g., BioRxiv/MedRxiv) with a CC-BY license at the time of journal submission, include funder acknowledgement(s) and data and software/code availability statements (which link to resources available at time of preprint submission), including if none were produced.
- Immediate open access at the time of publication.
 - All manuscripts must be made freely available immediately upon publication with a CC-BY license, without any embargo period (zero embargo).

- Data must be made freely available in an established, open repository no later than submission of the first journal manuscript based on the data, *or* a maximum of twelve months following the end of the grant period if there is no associated article or preprint.
 - Data underlying manuscripts, including those needed for reproducibility and independent verification of research results must be curated, cleaned, and made freely and publicly on the above timeline. For details on how to curate and clean the data, as well as guidance for appropriate repositories, please refer to the Open Science Policy.
- All preprints, articles, data, software, and code (if generated) must include a persistent identifier, such as a DOI (digital object identifier).

Recognition of biospecimens, protocols, and code

Publications performing new assays on LITE Pillar 3 biospecimens should cite the corresponding biospecimen identifier or accession number, where available, in the data acknowledgment section. Publications should also cite the relevant LITE protocol, analysis plan, or standard operating procedures where applicable.

All LITE Consortium-Authored publications involving computational analysis of LITE data, should deposit statistical code and relevant computational documentation in a publicly accessible repository and provide a persistent identifier, such as a DOI, at the time of article submission. The associated README should document the date of code creation, the date of data download or extraction, and note that the LITE database may evolve over time. Please refer to the MJFF Open Science Policy for additional guidance on how to prepare your code and associated README files.

Abstracts and Posters

All abstracts and posters utilizing LITE data, biospecimens, or derived resources must be submitted to the DPC for administrative compliance review. Due to the short turnaround time for abstracts and posters, DPC approval is not required prior to submission, however, the materials must still be submitted for tracking purposes.

Notification of Publication

All authors must notify the DPC upon publication of a submitted manuscript, abstract, or poster—including provision of the relevant DOI—so that a complete publication record can be maintained.

Unusual Situations

The LITE publication policy anticipates that investigators will follow these guidelines in good faith and that most analyses will be of reasonable scientific quality. However, unusual circumstances may arise.

Egregiously Poor Manuscripts: If a proposed manuscript is egregiously poor in language, scientific question, analytical methods, writing, or clarity, the LITE Steering Committee or DPC may recommend that it not be submitted without significant revision. If authors choose to submit such a manuscript anyway, possible actions may include withholding group authorship credit, requesting clarification that the manuscript does not represent a consortium-endorsed analysis, or revocation of future access privileges in serious cases.

Failure to Follow LITE Data or Biospecimen Use Agreements: If users inadvertently violate data or biospecimen use agreements, they are expected to self-correct once the issue is identified; willful violations may result in revocation of access.

Fraudulent Use of LITE Data or Specimens: It is possible that study data and biospecimens could be used inappropriately. This may result in immediate sanctions, including discontinuation of access and notification of supervisors or oversight bodies.

Journal Objections: If journal editors object to the group authorship format, the corresponding author must inform the DPC so that an acceptable solution can be reached that is consistent with this policy.

The Michael J. Fox Foundation and the LITE Steering Committee maintain the right to modify this policy by posting notice of such modifications at on this page. Any modification becomes effective immediately upon posting the modification unless otherwise stated.